Evaluation of the frequency of mutation genes in multidrug-resistant tuberculosis (MDR-TB) strains in Beijing, China.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
05 01 2021
Historique:
pubmed: 6 1 2021
medline: 21 4 2021
entrez: 5 1 2021
Statut: epublish

Résumé

The aim of this study was to explore the frequency and distribution of gene mutations that are related to isoniazid (INH) and rifampin (RIF)-resistance in the strains of the multidrug-resistant tuberculosis (MDR-TB) Mycobacterium tuberculosis (M.tb) in Beijing, China. In this retrospective study, the genotypes of 173 MDR-TB strains were analysed by spoligotyping. The katG, inhA genes and the promoter region of inhA, in which genetic mutations confer INH resistance; and the rpoB gene, in which genetic mutations confer RIF resistance, were sequenced. The percentage of resistance-associated nucleotide alterations among the strains of different genotypes was also analysed. In total, 90.8% (157/173) of the MDR strains belonged to the Beijing genotype. Population characteristics were not significantly different among the strains of different genotypes. In total, 50.3% (87/173) strains had mutations at codon S315T of katG; 16.8% (29/173) of strains had mutations in the inhA promoter region; of them, 5.5% (15/173) had point mutations at -15 base (C→T) of the inhA promoter region. In total, 86.7% (150/173) strains had mutations at rpoB gene; of them, 40% (69/173) strains had mutations at codon S531L of rpoB. The frequency of mutations was not significantly higher in Beijing genotypic MDR strains than in non-Beijing genotypes. Beijing genotypic MDR-TB strains were spreading in Beijing and present a major challenge to TB control in this region. A high prevalence of katG Ser315Thr, inhA promoter region (-15C→T) and rpoB (S531L) mutations was observed. Molecular diagnostics based on gene mutations was a useful method for rapid detection of MDR-TB in Beijing, China.

Identifiants

pubmed: 33397543
doi: 10.1017/S0950268820003131
pii: S0950268820003131
pmc: PMC8057498
doi:

Substances chimiques

Antitubercular Agents 0
Bacterial Proteins 0
Oxidoreductases EC 1.-
Catalase EC 1.11.1.6
katG protein, Mycobacterium tuberculosis EC 1.11.1.6
InhA protein, Mycobacterium EC 1.3.1.9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21

Références

FEMS Microbiol Rev. 2017 May 1;41(3):354-373
pubmed: 28369307
BMC Genomics. 2019 Mar 29;20(1):252
pubmed: 30922221
Microb Pathog. 2018 Apr;117:237-242
pubmed: 29486274
Antimicrob Agents Chemother. 2014;58(4):1997-2005
pubmed: 24419342
N Engl J Med. 2012 Jun 7;366(23):2161-70
pubmed: 22670902
Microbiol Spectr. 2014 Aug;2(4):MGM2-0014-2013
pubmed: 26104204
Epidemiol Infect. 2015 Jan;143(1):141-9
pubmed: 24667051
J Clin Microbiol. 2012 Jul;50(7):2404-13
pubmed: 22553245
J Antimicrob Chemother. 2011 Jul;66(7):1417-30
pubmed: 21558086
Antimicrob Agents Chemother. 2006 Aug;50(8):2640-9
pubmed: 16870753
Lancet Infect Dis. 2018 Dec;18(12):1350-1359
pubmed: 30342828
PLoS One. 2017 Mar 23;12(3):e0174197
pubmed: 28333978
BMC Infect Dis. 2018 Dec 14;18(1):658
pubmed: 30547765
Tuberculosis (Edinb). 2013 Jan;93(1):84-8
pubmed: 23146281
Clin Microbiol Infect. 2007 Jun;13(6):620-6
pubmed: 17403134
Antimicrob Agents Chemother. 2005 Mar;49(3):1229-31
pubmed: 15728936
BMC Infect Dis. 2018 Dec 29;18(1):710
pubmed: 30594126
Int J Tuberc Lung Dis. 2015 Nov;19(11):1276-89
pubmed: 26467578
J Clin Microbiol. 2003 Sep;41(9):4471-4
pubmed: 12958298
Antimicrob Agents Chemother. 2002 May;46(5):1417-24
pubmed: 11959577
Int J Infect Dis. 2018 Nov;76:109-119
pubmed: 29936318
PLoS One. 2014 Sep 19;9(9):e106787
pubmed: 25237849
Tuberculosis (Edinb). 2014 Mar;94(2):159-61
pubmed: 24325872
J Glob Antimicrob Resist. 2016 Jun;5:92-3
pubmed: 27436477
Antimicrob Agents Chemother. 2010 Mar;54(3):1075-81
pubmed: 20008778
J Antimicrob Chemother. 2007 Jun;59(6):1057-64
pubmed: 17442757
J Infect. 2015 Apr;70(4):335-45
pubmed: 25485999
Nature. 1992 Aug 13;358(6387):591-3
pubmed: 1501713
J Clin Microbiol. 2012 Mar;50(3):598-601
pubmed: 22170905
J Antibiot (Tokyo). 2014 Apr;67(4):291-7
pubmed: 24326341
Indian J Med Microbiol. 2015 Feb;33 Suppl:46-52
pubmed: 25657156
Antimicrob Agents Chemother. 2014 Jun;58(6):3475-80
pubmed: 24733464
Int J Infect Dis. 2009 Nov;13(6):673-8
pubmed: 19138546
Int J Tuberc Lung Dis. 2011 Jun;15(6):789-94
pubmed: 21575300

Auteurs

Y Liu (Y)

Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Tongzhou District, Beijing101149, China.

Y Sun (Y)

Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Tongzhou District, Beijing101149, China.

X Zhang (X)

Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Tongzhou District, Beijing101149, China.

Z Zhang (Z)

Beijing Changping Center for Tuberculosis Control and Prevention, Changping District, Beijing102200, China.

Q Xing (Q)

Central Laboratory, Beijing Research Institute for Tuberculosis Control, Xicheng District, Beijing100035, China.

W Ren (W)

Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Tongzhou District, Beijing101149, China.

C Yao (C)

Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Tongzhou District, Beijing101149, China.

J Yu (J)

Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Tongzhou District, Beijing101149, China.

B Ding (B)

Central Laboratory, Beijing Research Institute for Tuberculosis Control, Xicheng District, Beijing100035, China.

S Wang (S)

Central Laboratory, Beijing Research Institute for Tuberculosis Control, Xicheng District, Beijing100035, China.

C Li (C)

Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Tongzhou District, Beijing101149, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH